Filings · News reference
Niagen Bioscience Files Prospectus To Offer And Sell Common Stock Up To $50M
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com
The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed NAD+ supplement to
Niagen Bioscience Says It Expects Full-Year Ingredient Business Below Prior Year As Commercial Partners Face More Competitive Market; Sees Niagen Plus And New Skincare Partnerships Contributing Beginning 2027
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001386570/000138657026000043/cdcx-20260630.htm
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.